Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  Tirzepatide vs Cagrilintide: A Simple Research Comparison

Tirzepatide vs Cagrilintide: A Simple Research Comparison

Jun 11, 2026 4 min GLP-1 / Metabolic
TL;DR
Tirzepatide targets two gut hormones to cut blood sugar and body weight, while Cagrilintide mimics a satiety hormone often paired with semaglutide in trials. Research shows both produce meaningful weight loss, but through different biological pathways and at different studied doses. Understanding those differences helps you find the right charts and data to read.

Two Drugs, Two Different Approaches

Weight-loss research is moving fast. Two compounds get a lot of attention right now: Tirzepatide and Cagrilintide. They both reduce body weight in clinical trials, but they work in completely different ways. Let's break that down.

What Is Tirzepatide?

Tirzepatide is a dual agonist — it activates two receptors at once. Those receptors respond to GIP and GLP-1, two hormones your gut releases after eating. Think of GIP and GLP-1 as natural appetite-and-insulin signals. Tirzepatide mimics both at the same time.[6]

Because it hits two targets, tirzepatide tends to outperform single-target drugs in head-to-head research. In a large 2025 trial comparing it directly to semaglutide (a GLP-1-only drug), tirzepatide produced greater weight loss.[4] An earlier real-world study of over 41,000 patients found that people on tirzepatide were more than three times as likely to lose 15% or more of their body weight compared to those on semaglutide.[1]

In phase 3 trials for type 2 diabetes, tirzepatide was studied at doses of 5 mg, 10 mg, and 15 mg, injected once weekly.[6] For obesity specifically, the 15 mg weekly dose has been the main focus of late-stage research.[4]

What Is Cagrilintide?

Cagrilintide works differently. It's a long-acting analogue of amylin — a hormone your pancreas releases alongside insulin. Amylin tells your brain you're full and slows how fast your stomach empties. Cagrilintide copies that signal, but lasts much longer in the body.

In most recent research, cagrilintide isn't tested alone. It's paired with semaglutide (a GLP-1 drug) to form a combination called CagriSema. The idea is that hitting both the amylin pathway and the GLP-1 pathway together is more powerful than either alone.

The landmark REDEFINE 1 trial studied CagriSema — cagrilintide 2.4 mg plus semaglutide 2.4 mg — over 68 weeks. Participants without diabetes lost an average of 20.4% of their body weight, compared to just 3.0% on placebo.[2] A companion trial in people with type 2 diabetes showed similarly strong results.[3]

How Do the Research Doses Compare?

  • Tirzepatide: Phase 3 trials used 5 mg, 10 mg, and 15 mg once weekly (subcutaneous injection).[6] The 15 mg dose showed the largest weight reduction in obesity trials.[4]
  • Cagrilintide (as CagriSema): REDEFINE trials used 2.4 mg cagrilintide combined with 2.4 mg semaglutide, both once weekly.[2][3]
  • Escalation matters for both: Neither drug starts at its top dose. Participants in trials ramp up gradually over weeks to reduce nausea and other side effects.
  • Side effect profiles are similar: Gastrointestinal issues — nausea, vomiting, diarrhea — were the most common adverse events in trials for both compounds.[2][4]

Which One Should You Read About?

The honest answer: it depends on what you're curious about.

If you want to explore a drug that has a longer published track record across both diabetes and obesity, and has been compared head-to-head against other GLP-1 drugs, Tirzepatide's dosing charts are a great starting point.[1][5]

If you're interested in the newest wave of combination therapy — pairing an amylin mimic with a GLP-1 drug — then the Cagrilintide research charts cover the emerging REDEFINE trial data in detail.[2][3]

Either way, dose escalation schedules vary between studies, and raw numbers don't always translate neatly between research contexts. Use our calculator to explore how research dosing schedules are structured and what the milestones look like across different protocols.

The Bottom Line

Tirzepatide targets two gut-hormone receptors simultaneously. Cagrilintide targets the amylin pathway, usually alongside a GLP-1 drug. Both have shown impressive weight-loss results in rigorous clinical trials — just through different biological routes, at different doses, and in slightly different populations. Reading the original research carefully, with clear dose charts in front of you, is the best way to understand what each finding actually means.

This article is for educational purposes only. It is not medical advice. Always consult a qualified healthcare professional before making any health decisions.

Sources

  1. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. — JAMA internal medicine, 2024. PMID 38976257.
  2. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. — The New England journal of medicine, 2025. PMID 40544433.
  3. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. — The New England journal of medicine, 2025. PMID 40544432.
  4. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. — The New England journal of medicine, 2025. PMID 40353578.
  5. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. — BMJ (Clinical research ed.), 2024. PMID 38286487.
  6. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. — Lancet (London, England), 2021. PMID 34186022.
See the dosage chart — Tirzepatide
A dual incretin agonist researched for glycemic control and weight.
Tirzepatide

FAQ

What is the main difference between Tirzepatide and Cagrilintide?
Tirzepatide activates two gut-hormone receptors — GIP and GLP-1 — at the same time, making it a dual agonist.[6] Cagrilintide mimics amylin, a satiety hormone from the pancreas, and is typically studied alongside semaglutide as a combination therapy.[2] They target different biological pathways to reduce appetite and body weight.
What doses were used in the major Cagrilintide trials?
The REDEFINE 1 and REDEFINE 2 trials used cagrilintide at 2.4 mg once weekly combined with semaglutide at 2.4 mg once weekly — together called CagriSema. Participants without diabetes lost around 20.4% of their body weight over 68 weeks in REDEFINE 1, while the REDEFINE 2 trial focused on people with type 2 diabetes.[2][3]
How much weight loss did Tirzepatide show in research compared to other drugs?
In a real-world study of over 41,000 patients, people taking tirzepatide were over three times more likely to lose 15% or more of their body weight compared to those on semaglutide.[1] A 2025 head-to-head clinical trial also confirmed tirzepatide produced greater weight loss than semaglutide directly.[4]
Are the side effects of Tirzepatide and Cagrilintide similar?
Yes, broadly. Both compounds show gastrointestinal side effects as the most common issue in trials — things like nausea, vomiting, diarrhea, and constipation. In the REDEFINE 1 trial, about 79.6% of CagriSema participants reported GI events, most of which were mild to moderate.[2] Tirzepatide trials reported similar GI profiles.[4]
For research and educational use only. Not medical advice.